Profile data is unavailable for this security.
About the company
Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The Company owns and operates through Natural Point srl also in the food supplement sector.
- Revenue in EUR (TTM)2.27bn
- Net income in EUR423.12m
- Incorporated--
- Employees4.46k
- LocationRecordati Industria Chimica e Farmaceutica SpAVia Matteo Civitali, 1MILANO 20148ItalyITA
- Phone+39 2487871
- Fax+39 240073747
- Websitehttps://recordati.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Swedish Orphan Biovitrum AB (publ) | 2.21bn | 305.60m | 8.98bn | 1.81k | 28.83 | 2.68 | 14.34 | 4.06 | 10.06 | 10.06 | 72.98 | 108.01 | 0.3443 | 1.37 | 5.72 | 14,353,840.00 | 4.75 | 5.93 | 5.85 | 7.60 | 78.60 | 77.42 | 13.81 | 16.61 | 0.6225 | 4.35 | 0.325 | 0.00 | 17.74 | 19.34 | -8.68 | -0.0729 | 53.61 | -- |
| Ipsen SA | 3.44bn | 663.90m | 9.23bn | 5.33k | 13.86 | 2.25 | 8.99 | 2.69 | 7.94 | 8.15 | 41.11 | 48.94 | 0.5436 | 1.98 | 5.02 | 645,089.20 | 10.47 | 9.71 | 14.29 | 13.33 | 82.01 | 82.76 | 19.27 | 16.02 | 0.9771 | 46.18 | 0.0902 | 19.23 | 4.75 | 7.08 | 4.03 | 9.75 | -8.65 | 3.71 |
| Sichuan Biokin Pharmaceutical Co Ltd | 774.55m | 503.40m | 10.38bn | 2.09k | 20.61 | 18.46 | -- | 13.40 | 9.48 | 9.48 | 14.58 | 10.58 | 1.40 | 1.81 | 64.16 | 2,802,843.00 | 90.79 | -- | 138.20 | -- | 95.33 | -- | 64.99 | -- | 2.89 | -- | 0.2807 | -- | -20.11 | -- | -176.40 | -- | -- | -- |
| Catalent Inc | 4.24bn | -396.43m | 10.62bn | 16.90k | -- | 3.12 | 143.75 | 2.50 | -2.27 | -2.27 | 24.33 | 19.57 | 0.4482 | 4.92 | 3.27 | 261,656.80 | -4.19 | 0.0124 | -4.80 | 0.014 | 21.82 | 28.93 | -9.34 | 0.0278 | 1.93 | 0.7814 | 0.5821 | -- | 2.77 | 11.71 | -307.42 | -- | 8.44 | -- |
| Lupin Ltd | 2.44bn | 298.59m | 10.74bn | 21.87k | 36.07 | 6.04 | 25.75 | 4.41 | 57.42 | 57.42 | 468.54 | 342.91 | 0.8761 | 1.35 | 4.48 | 9,800,284.00 | 10.84 | 1.43 | 16.64 | 2.22 | 68.60 | 58.52 | 12.37 | 2.04 | 1.22 | 11.88 | 0.1797 | 75.03 | 20.25 | 6.41 | 345.15 | 30.18 | -1.17 | 9.86 |
| Zydus Lifesciences Ltd | 2.44bn | 486.32m | 10.86bn | 26.24k | 22.38 | 4.38 | 18.55 | 4.45 | 42.41 | 42.66 | 212.94 | 216.89 | 0.7495 | 1.75 | 5.01 | 8,187,310.00 | 15.00 | 9.05 | 19.96 | 14.01 | 71.43 | 61.15 | 20.01 | 14.33 | 1.58 | 217.94 | 0.0078 | 16.48 | 13.40 | 8.23 | 95.25 | 15.72 | -3.03 | -3.04 |
| Recordati Industria Chmc Frmctc SpA | 2.27bn | 423.12m | 10.90bn | 4.46k | 26.62 | 5.72 | 18.66 | 4.80 | 1.96 | 1.96 | 10.51 | 9.11 | 0.538 | 1.79 | 5.06 | 509,368.80 | 10.03 | 11.67 | 12.87 | 15.02 | 68.03 | 70.43 | 18.65 | 21.45 | 0.9325 | 8.51 | 0.4536 | 42.46 | 12.36 | 9.02 | 24.61 | 4.50 | 81.68 | 5.46 |
| Dr Reddy's Laboratories Ltd | 3.42bn | 606.96m | 11.50bn | 26.34k | 18.97 | 3.29 | 14.57 | 3.36 | 64.03 | 64.03 | 360.85 | 369.12 | 0.7379 | 1.37 | 3.90 | 11,420,450.00 | 13.31 | 11.37 | 18.14 | 16.02 | 70.69 | 65.86 | 18.03 | 14.63 | 1.36 | 30.69 | 0.1349 | 15.91 | 13.54 | 12.64 | 23.75 | 23.39 | 26.78 | 14.87 |
| Shionogi & Co Ltd | 2.60bn | 958.73m | 11.56bn | 4.96k | 11.59 | 1.38 | 10.77 | 4.45 | 180.74 | 180.74 | 489.15 | 1,519.70 | 0.292 | 0.9189 | 2.94 | 84,393,830.00 | 10.69 | 12.57 | 11.94 | 14.24 | 85.70 | 84.43 | 36.62 | 37.91 | 6.48 | -- | 0.0088 | 26.77 | 1.97 | 3.41 | -12.40 | 3.38 | 2.17 | 11.22 |
| Mankind Pharma Ltd | 1.25bn | 240.45m | 11.62bn | 19.54k | 48.41 | 9.68 | 39.84 | 9.28 | 52.70 | 52.70 | 274.57 | 263.69 | 0.8786 | 2.02 | 9.46 | 5,638,684.00 | 17.05 | -- | 21.79 | -- | 70.48 | -- | 19.41 | -- | 2.37 | 99.72 | 0.0428 | -- | 18.12 | -- | 49.23 | -- | -- | -- |
| Biomarin Pharmaceutical Inc | 2.64bn | 309.36m | 11.76bn | 3.40k | 38.65 | 2.26 | 29.02 | 4.45 | 1.66 | 1.66 | 14.02 | 28.41 | 0.4046 | 0.5242 | 4.08 | 809,411.60 | 4.74 | 0.7116 | 5.49 | 0.8079 | 78.95 | 76.30 | 11.71 | 2.05 | 2.62 | -- | 0.099 | 0.00 | 15.42 | 10.16 | 36.51 | -- | -5.74 | -- |
| Torrent Pharmaceuticals Ltd | 1.28bn | 204.91m | 12.19bn | 14.92k | 59.48 | 14.28 | 41.22 | 9.55 | 53.25 | 53.25 | 331.63 | 221.72 | 0.7525 | 1.22 | 6.35 | 7,525,369.00 | 12.08 | 8.34 | 17.95 | 13.03 | 75.52 | 71.78 | 16.06 | 13.18 | 0.7444 | 9.32 | 0.2941 | 61.65 | 11.51 | 6.93 | 33.02 | 30.58 | -8.17 | 26.93 |
| Beijing Wantai Biolog Pha Ent Co Ltd | 329.86m | -38.95m | 12.26bn | 3.84k | -- | 7.45 | -- | 37.18 | -0.2393 | -0.2393 | 1.97 | 9.82 | 0.1596 | 0.7843 | 0.7758 | 647,931.10 | -1.89 | 24.08 | -2.26 | 31.80 | 69.01 | 85.18 | -11.84 | 34.95 | 4.18 | -- | 0.0238 | 9.88 | -50.73 | 41.18 | -73.65 | 33.61 | 36.35 | -- |
Data as of Nov 25 2024. Currency figures normalised to Recordati Industria Chimica e Farmaceutica SpA's reporting currency: Euro EUR
14.69%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Oct 2024 | 7.38m | 3.53% |
| Invesco Asset Management Ltd.as of 22 Apr 2024 | 4.76m | 2.28% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 3.54m | 1.69% |
| Fundsmith LLPas of 22 Apr 2024 | 3.00m | 1.44% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 2.47m | 1.18% |
| Mawer Investment Management Ltd.as of 30 Jun 2024 | 2.35m | 1.12% |
| Norges Bank Investment Managementas of 22 Apr 2024 | 2.19m | 1.05% |
| Financi�re de l'�chiquier SAas of 22 Apr 2024 | 2.08m | 1.00% |
| Geode Capital Management LLCas of 21 Nov 2024 | 1.69m | 0.81% |
| Invesco Advisers, Inc.as of 22 Apr 2024 | 1.25m | 0.60% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
